HF
EGRX

HRT Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

HRT Financial’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-39,166
Closed -$761K – 3287
2023
Q2 		$761K Sell
39,166
-5,617
-13% -$133K 0.01% 1117
2023
Q1 		$1.27M Sell
44,783
-16,276
-27% -$483K 0.02% 827
2022
Q4 		$1.78M Buy
+61,059
New +$1.94M 0.03% 652
2022
Q3 		– Sell
-15,389
Closed -$683K – 3670
2022
Q2 		$683K Buy
15,389
+263
+2% +$12.1K 0.01% 1267
2022
Q1 		$748K Sell
15,126
-4,387
-22% -$211K 0.01% 1265
2021
Q4 		$993K Buy
19,513
+10,722
+122% +$556K 0.01% 1147
2021
Q3 		$490K Buy
+8,791
New +$433K ﹤0.01% 2013

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HRT Financial's EGRX Position: Q3 2023 in Review

HRT Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 39,166 shares — an estimated $761K sold.

HRT Financial first reported a position in EGRX in Q3 2021 and held it in 7 quarters. The position peaked at $1.78M in Q4 2022. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • HRT Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • HRT Financial sold 39,166 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $761K.
  • HRT Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2021 and held it in 7 quarters.
  • HRT Financial's Eagle Pharmaceuticals, Inc. position peaked at $1.78M in Q4 2022.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on HRT Financial's 13F filing for Q3 2023, filed 13 Nov 2023.